



genOway and Collectis close their disagreement

Paris, February 18, 2010 – genOway (Alternext: ALGEN) and Collectis indicate that the sublicense agreement dated September 7, 2001, relating to the patents and patent applications belonging to the pool WO90/11354 has been terminated as of December 30, 2008.

Collectis and Genoway have agreed on the consequences of such termination of the sublicense agreement, allowing Genoway to deliver the orders placed after the termination and before November 12, 2009. A visa of Collectis will be attached to the delivery of such orders.

Collectis and Genoway have therefore amicably and definitely closed their disagreement.

About genOway

genOway (ALTERNEXT-NYSE: ALGEN) is a biotechnology company developing genetically modified and high value-added research models for the bio-pharmaceutical, chemical, agrochemical and food industry as well as for academic research. With highly qualified scientific personnel, the company has a work force of 60 people and operates in over 22 countries in Europe, Asia and North America, supplying more than 285 customers. genOway is a leader in its market in terms of both size and customer portfolios. The company's development is founded upon both a broad and exclusive technology platform as well as strong intellectual property rights combining patents and licensing agreements. The company takes advantage of the global trend towards outsourcing the production of genetically modified research models by academic institutions and biopharmaceutical companies. To strengthen its technological position and benefit from worldwide business partners, genOway has signed strategic alliances with leading companies in their field: Charles River Laboratories (NYSE: CRL, a world leader in supplying laboratory animals), Invitrogen (NASDAQ: IVGN, world leader in supplying molecular biology reagents). For more information please go to www.genoway.com <<http://www.genoway.com>> .

Press relations: Marie Norbert - genOway - info@genoway.com

Contact for investors: Gaëlle Lebel , CFO – info@genoway.com

Milestones - press & investor relations: Bruno Arabian / Jacques-Olivier Costa
Tel.: +33 (0)1 75 44 87 40 / 42 – E-mail: barabian@milestones.fr / jocosta@milestones.fr

Warning: This press release contains certain prospective statements, either express or implied, concerning genOway and its activities. These statements rely on certain risks, either known or unknown, uncertainties or other factors, that may lead to genOway's actual results, financial condition, performance or achievements differing significantly from the results, financial condition, performance or achievements expressed or implied in these prospective statements. genOway is issuing this press release on the present date and is not committed to updating the prospective statements contained therein, either as a result of new information, future events or any other occurrence. For a detailed description of the types of risks or uncertainties likely to cause a difference between genOway's actual results, financial condition, performance or achievements and those contained in the prospective statements, please refer to the section on "Risk Factors" in the prospectus available on the genOway website: www.genoway.com.